Free Trial
NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Price, News & Analysis

vTv Therapeutics logo
$17.50 +1.04 (+6.32%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$17.70 +0.20 (+1.17%)
As of 07/10/2025 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About vTv Therapeutics Stock (NASDAQ:VTVT)

Key Stats

Today's Range
$16.50
$17.79
50-Day Range
$13.53
$22.46
52-Week Range
$12.12
$26.99
Volume
13,738 shs
Average Volume
22,952 shs
Market Capitalization
$55.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.50
Consensus Rating
Buy

Company Overview

vTv Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

VTVT MarketRank™: 

vTv Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 663rd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    vTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    vTv Therapeutics has received no research coverage in the past 90 days.

  • Read more about vTv Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of vTv Therapeutics is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of vTv Therapeutics is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    vTv Therapeutics has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about vTv Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.21% of the float of vTv Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    vTv Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in vTv Therapeutics has recently decreased by 3.74%, indicating that investor sentiment is improving.
  • Dividend Yield

    vTv Therapeutics does not currently pay a dividend.

  • Dividend Growth

    vTv Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.21% of the float of vTv Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    vTv Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in vTv Therapeutics has recently decreased by 3.74%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for vTv Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.20% of the stock of vTv Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 17.51% of the stock of vTv Therapeutics is held by institutions.

  • Read more about vTv Therapeutics' insider trading history.
Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

VTVT Stock Analysis - Frequently Asked Questions

vTv Therapeutics' stock was trading at $13.81 at the beginning of 2025. Since then, VTVT shares have increased by 26.7% and is now trading at $17.50.

vTv Therapeutics Inc. (NASDAQ:VTVT) announced its earnings results on Thursday, May, 15th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by $0.04.

Shares of vTv Therapeutics reverse split on the morning of Tuesday, November 21st 2023.The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

vTv Therapeutics (VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that vTv Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), NIO (NIO), VBI Vaccines (VBIV), Vaxart (VXRT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/15/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VTVT
CIK
1641489
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$36.00
Low Price Target
$35.00
Potential Upside/Downside
+102.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.46 million
Pretax Margin
-134,723.52%

Debt

Sales & Book Value

Annual Sales
$1.02 million
Price / Cash Flow
N/A
Book Value
$4.48 per share
Price / Book
3.91

Miscellaneous

Free Float
3,061,000
Market Cap
$55.83 million
Optionable
Not Optionable
Beta
0.58

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:VTVT) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners